Hongmei Xu

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 4

Top Topics

Acute Lymphoblastic Leukemia

Diffuse Large B Cell Lymphoma

Molecularly Imprinted

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Cancer chemotherapy and pharmacology

Clinical pharmacokinetics

This page only lists publications with an associated author ORCID identifier.

Publications

Babar Bashir, Judy S Wang, Gerald S Falchook, Elisa Fontana, Hendrick-Tobias Arkenau, Louise Carter, Rachel Galot, Bristi Basu, Alastair P Greystoke, Vivek Subbiah, Debra L Richardson, Hanna Orr, Gavin Bennett, Rajiv Sharma, Hongmei Xu, Paola Paganoni, Cong Xu, Carly Campbell, Meredith A McKean
Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Joseph A Tweed, Fern Adams-Dam, Jane Allanson, Kevin Holmes, Ryan Senior, Hongmei Xu, Mengyao Li, Gavin Bennett, Phil Jeffrey
Bioanalysis of the Bicycle ® toxin conjugate BT5528 and released monomethyl auristatin E via liquid chromatography-tandem mass spectrometry. Bioanalysis (2023)
Justin C Bader, Albiruni R Abdul Razak, Sharon Shacham, Hongmei Xu
Pharmacokinetics of Selinexor: The First-in-Class Selective Inhibitor of Nuclear Export. Clinical pharmacokinetics 60 (8) (2021)
Hongmei Xu, Hanbin Li, Russ Wada, Justin C Bader, Shijie Tang, Jatin Shah, Sharon Shacham
Selinexor population pharmacokinetic and exposure-response analyses to support dose optimization in patients with diffuse large B-cell lymphoma. Cancer chemotherapy and pharmacology 88 (1) (2021)